Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.
公佈的數據顯示，3.6%局部Sildenafil Cream在1,357次性體驗中對女性和她們的伴侶是安全且耐受的。
Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women.
使用3.6%局部Sildenafil Cream不會引起頭痛和麪部潮紅等與口服Sildenafil相關的常見副作用。
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced that safety and tolerability data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), has been published by The Journal of Sexual Medicine.
2024年8月26日，加州聖地亞哥（環球新聞社），Daré Bioscience, Inc.（納斯達克：DARE）宣佈，作爲女性健康和福祉創新領域的領導者，今日宣佈了Sildenafil Cream 3.6%在女性性喚起障礙（FSAD）的臨床探索性20億RESPOND研究中的安全性和耐受性數據已由《性醫學雜誌》發表。